RHOV

Across TCGA pan-cancer cohorts, RHOV Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RHOV data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RHOV Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RHOV expression acts as an unfavorable survival marker.

CESC and HNSC are the cancer types where RHOV Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.188	0.785	.001	12	view →
HNSC	OS	Median	All	0.191	0.751	.003	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RHOV–CESC (DFS)

Open the CESC breakdown →